Full Press Release Details
SAN RAFAEL, Calif. , Oct. 1, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Robert Baffi , Ph.D., President of Global Manufacturing and Technical Operations, will participate in a fireside discussion at the Jefferies Gene Therapy/Editing Summit on October 8, 2019 at 11:15am ET in New York. Dr. Baffi will also participate in the panel discussion on manufacturing, dose, and durability in gene therapy at 10:20am ET , which will not be available by webcast.
To access the live webcast presentation, please visit the investor section of the BioMarin website, www.biomarin.com . A replay will also be archived on the site for at least one week following each event.
About BioMarin BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com . Information on BioMarin's website is not incorporated by reference into this press release.
| Contacts: | |
| Investors | Media |
| Traci McCarty | Debra Charlesworth |
| BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
| (415) 455-7558 | (415) 455-7451 |
SOURCE BioMarin Pharmaceutical Inc.